QCG
VRTX icon

Quadrant Capital Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Quadrant Capital Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.55M Buy
5,716
+866
+18% +$404K 0.08% 209
2025
Q4 		$2.2M Sell
4,850
-825
-15% -$356K 0.07% 239
2025
Q3 		$2.22M Buy
5,675
+570
+11% +$238K 0.07% 223
2025
Q2 		$2.27M Sell
5,105
-233
-4% -$107K 0.08% 200
2025
Q1 		$2.59M Buy
5,338
+2,841
+114% +$1.32M 0.1% 134
2024
Q4 		$1.01M Buy
2,497
+12
+0.5% +$5.56K 0.07% 191
2024
Q3 		$1.16M Buy
2,485
+4
+0.2% +$1.92K 0.08% 181
2024
Q2 		$1.16M Buy
2,481
+135
+6% +$58.6K 0.09% 166
2024
Q1 		$981K Buy
2,346
+27
+1% +$11.4K 0.08% 185
2023
Q4 		$944K Buy
2,319
+72
+3% +$26.6K 0.08% 178
2023
Q3 		$781K Sell
2,247
-14
-0.6% -$4.9K 0.08% 186
2023
Q2 		$796K Sell
2,261
-80
-3% -$27K 0.08% 179
2023
Q1 		$738K Buy
2,341
+336
+17% +$101K 0.08% 192
2022
Q4 		$579K Sell
2,005
-7
-0.3% -$2.13K 0.07% 212
2022
Q3 		$583K Buy
2,012
+161
+9% +$46.3K 0.08% 184
2022
Q2 		$522K Buy
1,851
+329
+22% +$88.1K 0.07% 211
2022
Q1 		$397K Buy
1,522
+100
+7% +$23.7K 0.05% 276
2021
Q4 		$312K Buy
1,422
+230
+19% +$44.7K 0.04% 329
2021
Q3 		$216K Sell
1,192
-148
-11% -$28.9K 0.03% 368
2021
Q2 		$270K Sell
1,340
-112
-8% -$23.4K 0.04% 301
2021
Q1 		$312K Buy
1,452
+32
+2% +$7.03K 0.05% 252
2020
Q4 		$336K Buy
1,420
+155
+12% +$35.6K 0.06% 204
2020
Q3 		$344K Buy
1,265
+16
+1% +$4.41K 0.08% 170
2020
Q2 		$363K Sell
1,249
-1,263
-50% -$342K 0.08% 172
2020
Q1 		$594K Buy
2,512
+406
+19% +$93.1K 0.1% 177
2019
Q4 		$435K Buy
2,106
+229
+12% +$46.3K 0.05% 359
2019
Q3 		$305K Buy
1,877
+65
+4% +$11.5K 0.05% 428
2019
Q2 		$319K Buy
1,812
+266
+17% +$46.5K 0.05% 376
2019
Q1 		$270K Buy
1,546
+693
+81% +$128K 0.05% 393
2018
Q4 		$125K Buy
853
+169
+25% +$29.3K 0.03% 526
2018
Q3 		$122K Buy
684
+31
+5% +$5.52K 0.03% 346
2018
Q2 		$99K Sell
653
-48
-7% -$7.44K 0.03% 411
2018
Q1 		$100K Buy
701
+74
+12% +$12.1K 0.04% 412
2017
Q4 		$85K Buy
627
+3
+0.5% +$444 0.03% 454
2017
Q3 		$87K Buy
624
+37
+6% +$5.57K 0.04% 430
2017
Q2 		$69K Buy
587
+65
+12% +$7.82K 0.03% 448
2017
Q1 		$51K Buy
522
+64
+14% +$5.63K 0.02% 572
2016
Q4 		$29K Sell
458
-97
-17% -$7.89K 0.01% 628
2016
Q3 		$39K Buy
555
+52
+10% +$4.91K 0.03% 522
2016
Q2 		$36K Buy
503
+66
+15% +$5.7K 0.02% 508
2016
Q1 		$31K Sell
437
-518
-54% -$46.9K 0.02% 536
2015
Q4 		$116K Sell
955
-22
-2% -$2.66K 0.08% 224
2015
Q3 		$99K Buy
977
+85
+10% +$10.9K 0.07% 243
2015
Q2 		$109K Buy
+892
New +$112K 0.07% 236

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Quadrant Capital Group's VRTX Position: Q1 2026 in Review

Quadrant Capital Group increased its Vertex Pharmaceuticals (VRTX) stake by 18% in Q1 2026, buying an estimated $404K and bringing the position to 5,716 shares worth $2.55M. The position accounts for 0.08% of the portfolio, ranked #209.

Quadrant Capital Group first reported a position in VRTX in Q2 2015 and has held it in 44 quarters since. The position peaked at $2.59M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Quadrant Capital Group held 5,716 shares of Vertex Pharmaceuticals worth $2.55M as of Q1 2026.
  • Quadrant Capital Group bought 866 Vertex Pharmaceuticals shares in Q1 2026, an estimated $404K.
  • Vertex Pharmaceuticals made up 0.08% of Quadrant Capital Group's portfolio in Q1 2026, its #209 holding.
  • Quadrant Capital Group first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
  • Quadrant Capital Group's Vertex Pharmaceuticals position peaked at $2.59M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.